Study guide

3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators

Certified Medical Publication Professional CMPP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Preparation Strategy

1.1 ISMPP CMPP Certification Overview, Eligibility & Exam Format 1.2 Recertification, Continuing Education (CE) Credits & ISMPP U 1.3 Core Reference Hierarchy, Primary Documents & Test-Taking Strategy

2 Chapter 2: Publication Planning: Strategy, Environment & Scientific Platform

2.1 Medical Publication Lifecycle & Strategic Planning Frameworks 2.2 Therapeutic Landscape Analysis, Unmet Needs & Gap Analysis 2.3 Scientific Communication Platforms and Evidence-Based Language

3 Chapter 3: Publication Planning: Governance, Steering Committees & Venue Selection

3.1 Publication Steering Committees: Charters, Roles & Scientific Governance 3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators 3.3 Venue Selection, Open Access, and Congress Strategy

4 Chapter 4: Publication Planning: Operations, Contracting, Global Alignment & Compliance

4.1 Publication Agreements, Review Rights, Compensation & Disclosure 4.2 Milestones, Gantt Charts, Budgeting & Vendor/Agency Management 4.3 Global vs. Regional/Local Publication Alignment & Localization 4.4 Publication SOPs, Documentation, Quality Control & Audit Readiness

5 Chapter 5: Reporting Guidelines: Foundational Standards & Trial Reporting

5.1 EQUATOR and Design-Specific Reporting Guidelines 5.2 CONSORT 2025 & Flow Diagrams for Randomized Trials 5.3 SPIRIT 2025: Standard Protocol Items for Interventional Trials

6 Chapter 6: Reporting Guidelines: Observational, Reviews & Preclinical

6.1 PRISMA 2020 for Systematic Reviews & Meta-Analyses 6.2 STROBE & RECORD for Observational and Routinely Collected Data 6.3 ARRIVE 2.0 for In Vivo Animal Research

7 Chapter 7: Specialized Reporting, Plain Language Summaries & Congress Submissions

7.1 STARD 2015, CARE, and Specialized Reporting Guidelines 7.2 Plain-Language Summaries and Patient Partnership 7.3 GPCAP 2026: Congress Abstracts, Presentations & Encores 7.4 Digital Publication Features, Accessibility, and Social Dissemination

8 Chapter 8: Manuscript Lifecycle: Drafting, Peer Review, Open Access & Metrics

8.1 Manuscript Development, Author Review, and Sponsor Boundaries 8.2 Peer Review, Rebuttals, Revisions, and Appeals 8.3 Preprints, Creative Commons & Current Open-Access Requirements 8.4 Post-Publication Metrics and Correcting the Record

9 Chapter 9: Ethical Principles: GPP 2022, Authorship Criteria & Contributorship

9.1 Good Publication Practice 2022: Principles, Scope & Application 9.2 ICMJE Authorship Criteria and Qualification Scenarios 9.3 Nonauthor Contributors, Acknowledgments, and CRediT

10 Chapter 10: Ethics & Transparency: Ghostwriting, Writing Assistance, COI & Disclosure

10.1 Ghostwriting, Guest Authorship, and Authorship Disputes 10.2 Professional Medical Writing: Roles, Authorship, Disclosure & Funding 10.3 Disclosure of Interests and Publication Transparency 10.4 Open Payments, EFPIA Codes & Publication-Related Transfers of Value

11 Chapter 11: Compliance & Legal: Clinical Trial Registration, Data Sharing, Regulatory & Ethics

11.1 Trial Registration and Results Disclosure: US, EU, and ICMJE 11.2 Clinical-Trial Data-Sharing Statements and FAIR Principles 11.3 FDA SIUU Guidance & Promotional/Scientific Communication Boundaries 11.4 2024 Declaration of Helsinki, Ethics Review, Privacy & Copyright

3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators

Key Takeaways Explain This Topic AI

Strategic audience segmentation aligns clinical evidence delivery with the divergent decision-making needs of subspecialists, primary care providers, multidisciplinary healthcare teams, payers, patients, and health authorities.

Health Economics and Outcomes Research (HEOR) publications communicate QALYs, ICERs, budget impact models, and patient-reported outcomes (PROs) required by Health Technology Assessment (HTA) bodies and formulary committees.

Plain Language Summaries translate research into audience-appropriate language, preserve balanced benefits, harms, uncertainty, and funding disclosure, and should be tested with intended readers where feasible.

Clinical Study Reports (CSRs) fulfill exhaustive technical regulatory disclosure obligations, whereas peer-reviewed manuscripts deliver concise, clinically contextualized interpretations for medical practice.

Publication planning must systematically map specific publication types (primary efficacy, secondary analyses, sub-studies, reviews, letters) to targeted audience workflows and compliance boundaries.

Last updated: October 2026

3.2 Target Audience Identification: HCPs, Patients, Payers & Regulators

Quick Answer: Strategic audience segmentation ensures that clinical trial evidence is translated and delivered in formats appropriate for distinct stakeholder groups—including subspecialists, primary care providers, allied healthcare professionals, payers, patients, and regulatory bodies. Each audience possesses distinct information requirements, varying health literacy levels, and specific regulatory constraints. Effective publication plans map primary manuscripts, secondary analyses, HEOR models, plain language summaries (PLS), and regulatory summaries to these targeted constituencies.

Principles of Audience Segmentation in Medical Publication Planning

Clinical trial data do not exist in a vacuum; their ultimate utility depends on how effectively findings are communicated to the individuals who make treatment, reimbursement, and policy decisions. In publication planning, audience segmentation is the systematic process of identifying, categorizing, and prioritizing target stakeholder groups to determine the optimal timing, format, scientific depth, and venue for disseminating study results.

A common pitfall in publication management is adopting a "one-size-fits-all" approach—such as assuming that a single primary efficacy paper in a high-impact general medical journal satisfies all scientific communication needs. In reality, different audiences require distinct evidence packages to make informed decisions:

A tertiary subspecialist requires granular molecular mechanisms, subgroup survival curves, and biomarker stratification data.

A community physician requires clear diagnostic thresholds, comparative safety profiles against common alternatives, and practical patient selection criteria.

A clinical oncology nurse requires premedication protocols, infusion schedules, early toxicity recognition guides, and patient counseling strategies.

A hospital pharmacy director or formulary committee requires head-to-head comparative effectiveness data, drug stability details, and institutional cost impacts.

A health economist or reimbursement authority requires cost-utility analyses, Quality-Adjusted Life Years (QALYs), and budget impact projections.

A patient or caregiver requires clear explanations of potential benefits, symptom relief, daily functional impacts, administration burden, and common side effects, presented in non-technical language.

Strategic publication planning constructs an evidence dissemination matrix that sequences deliverables across the asset lifecycle to meet each audience's distinct requirements without violating ethical standards regarding redundant or premature publication. +-----------------------------------------------------------------------------------+

  • | THE MEDICAL PUBLICATION AUDIENCE SPECTRUM |
  • +-----------------------------------------------------------------------------------+
  • | HEALTHCARE PROFESSIONALS | ECONOMIC & POLICY | PATIENT COMMUNITY |
  • | - Tertiary Subspecialists | - HTA Bodies (NICE, IQWiG| - Diagnosed Patients |
  • | - General Practitioners | - Commercial Payers / PBM| - Family Caregivers |
  • | - Clinical Pharmacists | - Hospital P&T Committees| - Patient Advocates |
  • | - Specialized Nurses | - Regulatory Reviewers | - Lay Public |
  • +-----------------------------------------------------------------------------------+
  • Healthcare Professional (HCP) Stratification: Subspecialists, Generalists, and Allied Health

When tailoring scientific publications for healthcare practitioners, publication professionals must evaluate the clinical workflow and decision-making context of each clinician subgroup:

Subspecialists vs. Primary Care Physicians (PCPs)

Subspecialists (e.g., medical oncologists, interventional cardiologists, rheumatologists) represent the initial target audience for specialty therapeutics. They read specialized, organ-specific journals (e.g., Journal of Clinical Oncology , Circulation ) and attend international society congresses (e.g., ASCO, ESMO, AHA). Subspecialists demand rigorous biostatistical methodology, detailed pharmacodynamic and pharmacokinetic (PK/PD) sub-studies, exploratory biomarker correlations, and mechanistic rationale.

In contrast, primary care physicians (PCPs) and general internists treat multi-morbid patient populations and manage care across multiple therapeutic areas. They read broad general medical journals (e.g., NEJM , Lancet , JAMA , Annals of Internal Medicine , American Family Physician ). PCPs need publications that emphasize:

Clear disease identification criteria and validated screening algorithms.

Pragmatic safety warnings, routine laboratory monitoring intervals, and drug-drug interactions with common chronic medications (e.g., statins, antihypertensives).

Clear guidelines on when to initiate therapy versus when to refer to tertiary specialty care.

Multidisciplinary Allied Health: Nurses and Clinical Pharmacists

Modern patient care is delivered by multidisciplinary teams. Publication plans that neglect nurses and pharmacists fail to support real-world patient safety and adherence:

Specialty Nurses and Nurse Practitioners (NPs): Nurses manage hands-on drug administration, patient education, and early detection of adverse events. Nursing-focused publications (e.g., Clinical Journal of Oncology Nursing ) emphasize practical administration guidelines, extravasation management, infusion reaction protocols, toxicity grading, and supportive care strategies.

Clinical Pharmacists and Formulary Managers: Clinical pharmacists are essential members of hospital Pharmacy and Therapeutics (P&T) committees. They evaluate publications in specialized pharmacotherapy journals (e.g., Pharmacotherapy , Journal of Managed Care & Specialty Pharmacy ) focusing on product reconstitution, cold-chain storage stability, therapeutic drug monitoring, renal/hepatic dosing adjustments, and pharmacokinetic interactions.

Payer and Health Technology Assessment (HTA) Audiences: HEOR and Economic Value

Achieving regulatory approval does not guarantee patient access; a therapy must also achieve market access, reimbursement, and favorable formulary placement. Payers, reimbursement authorities, and Health Technology Assessment (HTA) agencies evaluate evidence through the lens of comparative clinical value, cost-effectiveness, and population health impact.

Key HEOR Disciplines and Metrics

Publication plans must incorporate dedicated Health Economics and Outcomes Research (HEOR) publications designed to address reimbursement hurdles:

Cost-Utility Analysis (CUA): Measures the cost per Quality-Adjusted Life Year (QALY) or Disability-Adjusted Life Year (DALY) gained.

Incremental Cost-Effectiveness Ratio (ICER): Evaluates the economic difference between the new intervention and the standard of care relative to their difference in clinical efficacy, calculated as the incremental cost divided by the incremental clinical benefit.

Budget Impact Models (BIMs): Calculate the net financial impact on a specific healthcare plan, national health system, or hospital budget over a 1- to 5-year time horizon.

Patient-Reported Outcomes (PROs) and Quality of Life (QoL): Validated instruments (e.g., EuroQol EQ-5D, SF-36, EORTC QLQ-C30) quantify how an intervention impacts physical functioning, pain, mental well-being, and daily independence.

Navigating Global HTA Requirements

HTA bodies across major global jurisdictions operate under differing statutory frameworks and valuation criteria:

United Kingdom (NICE): Focuses rigorously on cost per QALY gained, typically enforcing a cost-effectiveness threshold of £20,000 to £30,000 per QALY.

Germany (G-BA / IQWiG via AMNOG): Evaluates additional clinical benefit ( Zusatznutzen ) strictly against an appropriate comparative therapy (ACT), placing high evidentiary demands on direct head-to-head randomized trials rather than indirect comparisons.

United States (ICER - Institute for Clinical and Economic Review): An independent academic research organization that models value-based price benchmarks and budget impact thresholds for commercial and public payers.

Canada (CADTH / pCODR) and Australia (PBAC): Rigorous national cost-effectiveness and clinical utility reviews that directly determine inclusion on public provincial/federal drug formularies.

Note

HEOR and PRO publications must follow rigorous reporting guidelines just like clinical trials. Cost-effectiveness studies must comply with the CHEERS 2022 (Consolidated Health Economic Evaluation Reporting Standards) statement, while PRO data should be reported using the CONSORT-PRO extension.

Patient and Caregiver Audiences: The Ethical Mandate for Accessibility

Historically, biomedical publications were written exclusively by researchers for researchers, locking vital health discoveries behind paywalls and dense academic jargon. Over the past decade, a major paradigm shift led by patient advocacy groups, professional bodies, and progressive medical journals has established that patients have a fundamental ethical right to understand research derived from their clinical trial participation.

Plain Language Summaries (PLS)

A Plain Language Summary (PLS) is an objective, non-promotional summary of a scientific publication written specifically for non-specialists, including patients, family caregivers, patient advocates, and non-specialist clinicians.

Under GPP 2022 and professional PLS guidance:

Target Readability: Plain language text should be calibrated to a audience-appropriate reading level (using validated readability metrics such as the Flesch-Kincaid Grade Level or Coleman-Liau Index).

Core Formats: PLS can be published as:

Embedded PLS: A dedicated plain-language abstract published within the primary manuscript alongside the traditional medical abstract.

Standalone Plain Language Summary of Publication (PLSP): A separate, peer-reviewed, citable article published in an open-access journal.

Visual / Infographic PLS: Graphical summaries depicting trial design, key results, and safety in accessible, visual layouts.

Audio/Video PLS: Digital author narrations explaining study context and outcomes.

Non-Promotional Standards: PLS must never function as marketing or promotional collateral. They must objectively balance efficacy benefits with adverse events and risks, disclose trial funding, and state that patients should consult their personal healthcare provider regarding medical decisions.

Tip

Best practice in PLS development involves partnering directly with patient co-authors or patient advocacy representatives during drafting. Patient contributors review text for clarity, tone, and clinical relevance to ensure that the patient perspective is authentic and accessible.

Regulatory Authorities and Public Disclosure: CSRs vs. Peer-Reviewed Manuscripts

A critical responsibility of the publication professional is managing the intersection between mandatory regulatory disclosures and voluntary peer-reviewed journal publications. While both communicate clinical trial data, they serve fundamentally different legal, operational, and clinical purposes.

Dimension Clinical Study Report (CSR) Peer-Reviewed Manuscript

Primary Purpose Regulatory approval and statutory compliance Peer education, clinical dialogue, and scientific debate

Target Audience Regulatory agency reviewers (FDA, EMA, PMDA, NMPA) Practicing physicians, researchers, and clinicians

Document Length Hundreds to thousands of pages (including appendices) Typically 3,000 to 4,500 words

Level of Detail Exhaustive individual patient listings, CRFs, SAS code Synthesized summary statistics, key figures, and tables

Contextual Discussion Factual, regulatory-focused; minimal external context Broad contextualization within existing literature

Peer Review Mechanism Reviewed by regulatory scientific assessment teams Independent, blinded or open academic peer review

Public Availability Redacted disclosure via clinical registries (CTIS/EMA) Indexing in MEDLINE/PubMed, journal website access

Disclosure Coordination: ClinicalTrials.gov, EU CTR, and the ICMJE Rule

Under statutory mandates such as FDAAA 801 in the United States and the EU Clinical Trials Regulation (EU CTR 536/2014) operating via the Clinical Trials Information System (CTIS) in Europe, clinical trial sponsors are legally obligated to post tabular summary results to public registries within 12 months of the Primary Completion Date (PCD) .

Historically, authors feared that posting tabular trial results to ClinicalTrials.gov or CTIS would violate the "Ingelfinger Rule" (the journal policy prohibiting prior publication or duplicate submission). The ICMJE has explicitly clarified that:

Posting required tabular results, protocol summaries, and brief safety data to a recognized public clinical trial registry within statutory deadlines does not constitute prior publication.

Medical journal editors will not reject manuscripts based on timely registry disclosure required by law.

Authors must cite the clinical trial registration number (e.g., NCT identifier) in all manuscript drafts and abstracts.

Strategic Evidence Mapping: Aligning Publication Types with Stakeholder Needs

To prevent disjointed publication activities, publication professionals develop a comprehensive delivery matrix mapping publication formats to target stakeholders and regulatory constraints:

Publication Format Target Stakeholder Audience Core Content Focus Key Regulatory / Governance Boundary

Primary Efficacy MS Subspecialists, general practitioners, regulatory bodies Primary/secondary endpoints, overall safety, methodology Must report prespecified protocol endpoints objectively

Secondary / Subgroup MS Subspecialists, academic clinical researchers Stratified efficacy, biomarker correlations, long-term Must clearly label post-hoc or exploratory analyses

HEOR / Cost-Utility MS Payers, HTA reviewers (NICE, IQWiG), P&T committees QALYs, ICERs, budget impact, real-world resource use Adherence to CHEERS 2022 guidelines; no unsubstantiated

Plain Language Summary Patients, caregivers, patient advocacy organizations Non-technical summary of trial results and safety 6th-8th grade readability; strictly non-promotional

Clinical Review Article General practitioners, trainees, community clinicians Disease landscape, treatment algorithms, clinical trials Must declare all author COIs and commercial funding

Congress Abstract/Poster Active conference delegates, specialist researchers Rapid, preliminary, or updated trial efficacy/safety Strict adherence to congress embargo and encore rules